Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Blood Volume Assessment in COVID-19 and Bacterial Sepsis
NCT04517695 · View on ClinicalTrials.gov ↗
Study Summary
In patients with SARS-CoV-2 or bacterial infection admitted to the intensive care unit (ICU), the state of the intravascular volume, the characteristics of the blood volume components, and the development of a vascular leak is currently unknown. The relationship of these parameters with parameters of cardiac performance, lung edema and sublingual microcirculatory perfusion parameters have never been studied.
Conditions Studied
Interventions
- DEVICE BVA-100
- DEVICE Transpulmonary Thermodilution (TPTD)
- DEVICE Sublingual Microcirculation
Study Locations (3)
Maryland
- Uniformed Services University of the Health Sciences — Bethesda
New York
- NYU Langone Health — New York
North Carolina
- Wake Forest Baptist Health — Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2023-04-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04517695
The ClinicalTrials.gov registry entry for NCT04517695 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,204 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Covid19 appearing as the primary indexed condition, and to 3 interventions — of which BVA-100 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04517695 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Maryland, New York, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04517695 about?
NCT04517695 is a clinical study titled "Blood Volume Assessment in COVID-19 and Bacterial Sepsis". In patients with SARS-CoV-2 or bacterial infection admitted to the intensive care unit (ICU), the state of the intravascular volume, the characteristics of the blood volume components, and the development of a vascular leak is currently unknown. The relationship of these parameters with parameters o...
What is the current status of trial NCT04517695?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2020-08-01. Estimated completion is 2023-04-09.
What conditions does trial NCT04517695 study?
This clinical trial studies the following conditions: Covid19, Acute Respiratory Distress Syndrome, Bacterial Infections, Bacterial Sepsis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04517695?
The interventions under investigation include: BVA-100 (DEVICE), Transpulmonary Thermodilution (TPTD) (DEVICE), Sublingual Microcirculation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04517695?
This trial is sponsored by NYU Langone Health, which has 1,204 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04517695 being conducted?
This trial has 3 study locations across Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.